Lawrence Alleva Net Worth

The estimated Net Worth of Lawrence M Alleva is at least $1.09 Million dollars as of 1 December 2023. Mr. Alleva owns over 680 units of Galera Therapeutics Inc stock worth over $683 and over the last 12 years he sold GRTX stock worth over $903,394. In addition, he makes $185,079 as Independent Director at Galera Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Alleva GRTX stock SEC Form 4 insiders trading

Lawrence has made over 15 trades of the Galera Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 680 units of GRTX stock worth $60,241 on 1 December 2023.

The largest trade he's ever made was buying 47,280 units of Galera Therapeutics Inc stock on 17 December 2018 worth over $39,715. On average, Lawrence trades about 1,470 units every 56 days since 2013. As of 1 December 2023 he still owns at least 9,362 units of Galera Therapeutics Inc stock.

You can see the complete history of Mr. Alleva stock trades at the bottom of the page.

Lawrence Alleva biography

Lawrence M. Alleva CPA serves as Independent Director of the Company. He is a former partner with PricewaterhouseCoopers LLP (PwC), where he worked for 39 years from 1971 until his retirement in June 2010, including 28 years as a partner. Mr. Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm’s Assurance Practice from 2006 until 2010. Mr. Alleva currently serves on the board of directors of Bright Horizons Family Solutions, Inc., Mersana Therapeutics, Inc. and Adaptimmune Therapeutics PLC and chairs the audit committee for those companies. He previously served on the board of directors of TESARO, Inc. through the time of its sale to GSK in January 2019, Mirna Therapeutics, Inc. which was merged into another company in 2017 and of GlobalLogic, Inc. through the sale of the company in 2013, and he chaired the audit committee for those companies. Mr. Alleva is a Certified Public Accountant (inactive). He received a B.S. degree in Accounting from Ithaca College and attended Columbia University’s Executive M.B.A. non-degree program.

What is the salary of Lawrence Alleva?

As the Independent Director of Galera Therapeutics Inc, the total compensation of Lawrence Alleva at Galera Therapeutics Inc is $185,079. There are 8 executives at Galera Therapeutics Inc getting paid more, with J. Mel Sorensen having the highest compensation of $2,465,100.

How old is Lawrence Alleva?

Lawrence Alleva is 70, he's been the Independent Director of Galera Therapeutics Inc since 2019. There are 2 older and 15 younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.

What's Lawrence Alleva's mailing address?

Lawrence's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.

Insiders trading at Galera Therapeutics Inc

Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ..., and Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.

What does Galera Therapeutics Inc do?

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Complete history of Mr. Alleva stock trades at Adaptimmune Therapeutics Plc, Bright Horizons Family Solutions, Mersana Therapeutics Inc, and Galera Therapeutics Inc

Galera Therapeutics Inc executives and stock owners

Galera Therapeutics Inc executives and other stock owners filed with the SEC include:

• J. Mel Sorensen,
  President, Chief Executive Officer, Director
• Christopher Degnan,
  Chief Financial Officer
• Robert Beardsley,
  Chief Operating Officer
• Dr. J. Mel Sorensen,
  CEO, Pres & Director
• Christopher Degnan,
  CFO & Sec.
• Dr. Robert A. Beardsley,
  Co-Founder & COO
• Arthur Fratamico,
  Chief Business Officer
• Jon Holmlund,
  Chief Medical Officer
• Lawrence Alleva,
  Independent Director
• Michael Powell,
  Independent Chairman of the Board
• Emmett Cunningham,
  Director
• Kevin Lokay,
  Independent Director
• Linda West,
  Independent Director
• Joel Sussman,
  Chief Accounting Officer
• Mark J. Bachleda M.B.A., Pharm.D.,
  Chief Commercial Officer
• Arthur J. Fratamico,
  Chief Bus. Officer
• Dr. Jon T. Holmlund,
  Chief Medical Officer
• Jennifer Evans Stacey Esq.,
  Chief Legal & Compliance Officer and Sec.
• Dr. Dennis P. Riley Ph.D.,
  Chief Scientific Officer
• Joel F. Sussman,
  Chief Accounting Officer & Treasurer
• Bioventures Ltd Novartis Ag...,
  
• Chris Degnan,
  Chief Financial Officer
• Jason Fuller,
  Director
• Iv A, L.P.Clarus Iv B, L.P....,
  
• Group Inc Blackstone Group ...,
  
• Clarus Gp L.P.Blackstone Cl...,
  
• Enterprise Associates 14, L...,
  
• Venture Partners Ix, L.P.So...,
  
• Dennis Riley,
  Chief Scientific Officer
• Holdings A/S Novo,
  10% owner
• Mark Bachleda,
  Chief Commercial Officer
• Jennifer Evans Stacey,
  See Remarks
• Yair Schneid,
  10% owner
• Eugene P. Kennedy,
  Chief Medical Officer
• Mel Sorensen,
  President and CEO